Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Starpharma's DNT Priostar(TM) Dendrimers Significantly Improve Properties of Marketed Fluorescent Reagents

Abstract:
Starpharma (ASX:SPL, OTCQX: SPHRY), through its US subsidiary company Dendritic
Nanotechnologies Inc (DNT), has found that DNT's Priostar(TM) dendrimer
technology can be used to amplify the signal and increase the duration of
the signal (photostability) of existing products in the multi-billion
dollar fluorescent reagents market. The company has filed a patent for the
discovery through DNT.

Starpharma's DNT Priostar(TM) Dendrimers Significantly Improve Properties of Marketed Fluorescent Reagents

MELBOURNE, Australia | Posted on May 7th, 2007

Fluorescent reagents are used extensively in laboratories for high-
throughput screening, diagnostic immunoassays, microarrays, fluorescence
microscopy, genomics and proteomics. Strong signals and photostability are
extremely important properties as they increase the sensitivity of
detection methods and facilitate measurement of the signal, respectively.

Increased sensitivity is needed to study disease markers that are
present at very low levels -- often below those detectable with current
technologies.

Using its Priostar(TM) technology, DNT has created dye-dendrimer
complexes from various commercial dyes that show significantly enhanced
fluorescent (greater than 10 fold) and photostability (greater than 4
fold), in addition to improved solubility in water.

Preliminary testing has shown that the enhanced properties of
Priostar(TM) dendrimer-dye complexes are retained after attachment to an
antibody, an integral component for many of the applications of fluorescent
dyes.

"Market feedback indicates that the scientific community and industry
users of these products will highly value the availability of reagents with
increased sensitivity and photostability," said Dr. Lori Reyna, director of
life sciences at DNT. Scientists are always keen to increase the
sensitivity of detection and quantitation methods."

DNT will partner with established leaders in the diagnostic and
research reagent industries through licensing and supply agreements. The
initial commercialization target will be the research reagent and in vitro
diagnostic markets. DNT is currently in preliminary commercialization
discussions with the market leaders in the area of fluorescence reagents.

####

About Starpharma
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in
the development of dendrimer nanotechnology for pharmaceutical,
life-science and other applications. SPL is principally composed of two
operating companies, Starpharma Pty Ltd in Melbourne, Australia and
Dendritic Nanotechnologies, Inc in Michigan, USA.

For more information, please click here

Contacts:
Media:
Rebecca Wilson
Buchan Consulting
Tel: +61 2 9237 2800
Mob: +61 417 382 391


Starpharma:
Dr Jackie Fairley
Chief Executive Officer Starpharma Holdings Ltd
+61 3 8532 2704

Dr Robert Berry
President
DNT
Tel: 989.774.1799


Ben Rogers
Company Secretary
Starpharma Holdings Ltd
+61 3 8532 2702


Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Arrowhead to Present at BioCentury's NewsMakers in the Biotech Industry Conference September 19th, 2014

The Pocket Project will develop a low-cost and accurate point-of-care test to diagnose Tuberculosis: ICN2 holds a follow-up meeting of the Project on September 18th - 19th September 18th, 2014

New non-invasive technique could revolutionize the imaging of metastatic cancer September 17th, 2014

Recruiting bacteria to be technology innovation partners: September 17th, 2014

Announcements

Iranian Scientists Separate Zinc Ion at Low Concentrations September 20th, 2014

Arrowhead to Present at BioCentury's NewsMakers in the Biotech Industry Conference September 19th, 2014

SouthWest NanoTechnologies (SWeNT) Receives NIST Small Business Innovation Research (SBIR) Phase 1 Award to Produce Greater than 99% Semiconducting Single-Wall Carbon Nanotubes September 19th, 2014

Toward optical chips: A promising light source for optoelectronic chips can be tuned to different frequencies September 19th, 2014

Nanobiotechnology

Arrowhead to Present at BioCentury's NewsMakers in the Biotech Industry Conference September 19th, 2014

CiQUS researchers design an artificial nose to detect DNA differentiation with single nucleotide resolution September 18th, 2014

Biosensors Get a Boost from Graphene Partnership: $5 Million Investment Supports Dozens of Jobs and Development of 300mm Fabrication Process and Wafer Transfer Facility September 18th, 2014

Recruiting bacteria to be technology innovation partners: September 17th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE